Irhythm Technologies (IRTC) Stock Forecast & Price Target

Compare

588 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IRTC Analyst Ratings

Strong Buy

13 Buy

1 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Irhythm

Technologies

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IRTC Stock 12 Month Forecast

Average Price Target

$222.83

▲(38.97% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Irhythm Technologies in the last 3 months. The average price target is $222.83 with a high forecast of $244.00 and a low forecast of $205.00. The average price target represents a 38.97% change from the last price of $160.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"89":"$89","128":"$128","167":"$167","206":"$206","245":"$245"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":244,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$244.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":222.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$222.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":205,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$205.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[89,128,167,206,245],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.44,182.56,187.68,192.8,197.92,203.04,208.16,213.28,218.4,223.51999999999998,228.64,233.76,238.88,{"y":244,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.44,180.93153846153845,184.42307692307693,187.9146153846154,191.40615384615384,194.8976923076923,198.38923076923078,201.88076923076923,205.3723076923077,208.86384615384617,212.35538461538462,215.84692307692308,219.33846153846156,{"y":222.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.44,179.56,181.68,183.8,185.92,188.04,190.16,192.28,194.4,196.52,198.64,200.76,202.88,{"y":205,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":90.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.16,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.97,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.45,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.74,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.44,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$244.00

Average Price Target$222.83

Lowest Price Target$205.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Stephanie Piazzola

Bank of America Securities

$225

Buy

40.33%

Upside

Reiterated

01/16/26

Analysts Are Bullish on Top Healthcare Stocks: Gilead Sciences (GILD), Progyny (PGNY)

Richard Newitter

Truist Financial

Buy

―

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (NASDAQ: IRTC), Charles River Labs (NYSE: CRL) and Butterfly Network (NYSE: BFLY)

William Plovanic

Canaccord Genuity

$212

Buy

32.22%

Upside

Reiterated

01/13/26

Canaccord Genuity Remains a Buy on Irhythm Technologies (IRTC)

Nathan Treybeck

Wells Fargo

$220→$225

Buy

40.33%

Upside

Reiterated

01/13/26

Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Adaptive Biotechnologies (ADPT)

Brandon Vazquez

William Blair

Buy

―

Reiterated

01/12/26

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (NASDAQ: IRTC), Butterfly Network (NYSE: BFLY) and Mereo Biopharma Group Plc (NASDAQ: MREO)

David Saxon

Needham

$244

Buy

52.18%

Upside

Reiterated

01/12/26

Irhythm Technologies: Durable Growth, Margin Expansion, and Beat-and-Raise Potential Support Buy Rating

David Roman

Goldman Sachs

$202→$211

Hold

31.60%

Upside

Reiterated

01/09/26

iRhythm price target raised to $211 from $202 at Goldman SachsiRhythm price target raised to $211 from $202 at Goldman Sachs

Vijay Kumar

Evercore ISI

$194→$210

Buy

30.97%

Upside

Upgraded

01/05/26

iRhythm upgraded to Outperform from In Line at Evercore ISIiRhythm upgraded to Outperform from In Line at Evercore ISI

David Rescott

Robert W. Baird

$235→$220

Buy

37.21%

Upside

Reiterated

12/16/25

Robert W. Baird Remains a Buy on Irhythm Technologies (IRTC)

Joanne Wuensch

Citi

$242

Buy

50.93%

Upside

Reiterated

12/11/25

Citi Keeps Their Buy Rating on Irhythm Technologies (IRTC)

Patrick Wood

Morgan Stanley

$195→$205

Buy

27.85%

Upside

Reiterated

12/02/25

iRhythm price target raised to $205 from $195 at Morgan StanleyiRhythm price target raised to $205 from $195 at Morgan Stanley

Marie Thibault

BTIG

$215

Buy

34.09%

Upside

Reiterated

11/17/25

Confident Outlook for Irhythm Technologies Amid Proposed Medicare Policy Changes

Suraj Kalia

Oppenheimer

$175→$225

Buy

40.33%

Upside

Reiterated

10/31/25

iRhythm price target raised to $225 from $175 at OppenheimeriRhythm price target raised to $225 from $175 at Oppenheimer

Allen Gong

J.P. Morgan

$190→$240

Buy

49.68%

Upside

Reiterated

10/31/25

iRhythm price target raised to $240 from $190 at JPMorganiRhythm price target raised to $240 from $190 at JPMorgan

Eugene Mannheimer

Freedom Capital Markets

$205

Buy

27.85%

Upside

Initiated

10/13/25

Irhythm Technologies (IRTC) Receives a Buy from Freedom Capital Markets

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Stephanie Piazzola

Bank of America Securities

$225

Buy

40.33%

Upside

Reiterated

01/16/26

Analysts Are Bullish on Top Healthcare Stocks: Gilead Sciences (GILD), Progyny (PGNY)

Richard Newitter

Truist Financial

Buy

―

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (NASDAQ: IRTC), Charles River Labs (NYSE: CRL) and Butterfly Network (NYSE: BFLY)

William Plovanic

Canaccord Genuity

$212

Buy

32.22%

Upside

Reiterated

01/13/26

Canaccord Genuity Remains a Buy on Irhythm Technologies (IRTC)

Nathan Treybeck

Wells Fargo

$220→$225

Buy

40.33%

Upside

Reiterated

01/13/26

Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Adaptive Biotechnologies (ADPT)

Brandon Vazquez

William Blair

Buy

―

Reiterated

01/12/26

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (NASDAQ: IRTC), Butterfly Network (NYSE: BFLY) and Mereo Biopharma Group Plc (NASDAQ: MREO)

David Saxon

Needham

$244

Buy

52.18%

Upside

Reiterated

01/12/26

Irhythm Technologies: Durable Growth, Margin Expansion, and Beat-and-Raise Potential Support Buy Rating

David Roman

Goldman Sachs

$202→$211

Hold

31.60%

Upside

Reiterated

01/09/26

iRhythm price target raised to $211 from $202 at Goldman SachsiRhythm price target raised to $211 from $202 at Goldman Sachs

Vijay Kumar

Evercore ISI

$194→$210

Buy

30.97%

Upside

Upgraded

01/05/26

iRhythm upgraded to Outperform from In Line at Evercore ISIiRhythm upgraded to Outperform from In Line at Evercore ISI

David Rescott

Robert W. Baird

$235→$220

Buy

37.21%

Upside

Reiterated

12/16/25

Robert W. Baird Remains a Buy on Irhythm Technologies (IRTC)

Joanne Wuensch

Citi

$242

Buy

50.93%

Upside

Reiterated

12/11/25

Citi Keeps Their Buy Rating on Irhythm Technologies (IRTC)

Patrick Wood

Morgan Stanley

$195→$205

Buy

27.85%

Upside

Reiterated

12/02/25

iRhythm price target raised to $205 from $195 at Morgan StanleyiRhythm price target raised to $205 from $195 at Morgan Stanley

Marie Thibault

BTIG

$215

Buy

34.09%

Upside

Reiterated

11/17/25

Confident Outlook for Irhythm Technologies Amid Proposed Medicare Policy Changes

Suraj Kalia

Oppenheimer

$175→$225

Buy

40.33%

Upside

Reiterated

10/31/25

iRhythm price target raised to $225 from $175 at OppenheimeriRhythm price target raised to $225 from $175 at Oppenheimer

Allen Gong

J.P. Morgan

$190→$240

Buy

49.68%

Upside

Reiterated

10/31/25

iRhythm price target raised to $240 from $190 at JPMorganiRhythm price target raised to $240 from $190 at JPMorgan

Eugene Mannheimer

Freedom Capital Markets

$205

Buy

27.85%

Upside

Initiated

10/13/25

Irhythm Technologies (IRTC) Receives a Buy from Freedom Capital Markets

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Irhythm Technologies

3 Months

xxx

Success Rate

17/25 ratings generated profit

Average Return

+9.15%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.00% of your transactions generating a profit, with an average return of +9.15% per trade.

1 Year

Richard NewitterTruist Financial

Success Rate

12/20 ratings generated profit

Average Return

+33.81%

reiterated a buy rating 13 days ago

Copying Richard Newitter's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +33.81% per trade.

2 Years

xxx

Success Rate

19/20 ratings generated profit

Average Return

+63.80%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.00% of your transactions generating a profit, with an average return of +63.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IRTC Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IRTC has received 15 Buy Ratings, 17 Hold Ratings, and 1 Sell Ratings. IRTC average Analyst price target in the past 3 months is 222.83.

Each month's total comprises the sum of three months' worth of ratings.

IRTC Financial Forecast

IRTC Earnings Forecast

Next quarter’s earnings estimate for IRTC is $0.01 with a range of -$0.12 to $0.14. The previous quarter’s EPS was -$0.16. IRTC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year IRTC has Performed in-line its overall industry.

IRTC Sales Forecast

Next quarter’s sales forecast for IRTC is $201.25M with a range of $199.00M to $207.30M. The previous quarter’s sales results were $192.88M. IRTC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year IRTC has Performed in-line its overall industry.

IRTC Stock Forecast FAQ

What is IRTC’s average 12-month price target, according to analysts?

Based on analyst ratings, Irhythm Technologies’s 12-month average price target is 222.83.

What is IRTC’s upside potential, based on the analysts’ average price target?

Irhythm Technologies has 38.97% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IRTC a Buy, Sell or Hold?

Irhythm Technologies has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.

What is Irhythm Technologies’s price target?

The average price target for Irhythm Technologies is 222.83. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $244.00 ,the lowest forecast is $205.00. The average price target represents 38.97% Increase from the current price of $160.34.

What do analysts say about Irhythm Technologies?

Irhythm Technologies’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of IRTC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Irhythm Technologies (IRTC) Stock Forecast & Price Target

IRTC Analyst Ratings

IRTC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Irhythm Technologies

IRTC Analyst Recommendation Trends

IRTC Financial Forecast

IRTC Earnings Forecast

IRTC Sales Forecast

IRTC Stock Forecast FAQ

Detailed List of Analyst Forecasts